Evidence map›Paper›PMID 39895532›Full record

Observational studyJournal of the American Heart Association2025

Prior Anticoagulation and Risk of Hemorrhagic Transformation in Acute Stroke: A Post Hoc Analysis of the PRODAST Study.

Gerrit M Grosse, Anika Hüsing, Andreas Stang, Nils Kuklik, Marcus Brinkmann, Martin Grond, Jens D Rollnik, Lars Marquardt, Andrea Kraft, Eckhard Schlemm and 4 more

Registry-linked trialAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02507856 (Prospective Record Of the Use of Dabigatran in Patients With Acute Stroke or TIA), which is not on this map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02507856 completednot on this map

Prospective Record Of the Use of Dabigatran in Patients With Acute Stroke or TIA

Typeobservational_patient_registrySponsorUniversity Hospital, EssenRan2015 to 2022Enrolled10,044ConditionsBrain Ischemia With Non-valvular Atrial Fibrillation, Transient Ischemic Attack With Non-valvular Atrial Fibrillation
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Early versus late anticoagulation treatment after acute ischemic stroke with atrial fibrillation: a meta-analysis of randomized controlled trials.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Gerrit M GrosseInstitute for Medical Informatics, Biometry and Epidemiology, Medical Faculty University Duisburg-Essen Essen Germany.ORCID 0000-0002-5335-9880
Anika HüsingInstitute for Medical Informatics, Biometry and Epidemiology, Medical Faculty University Duisburg-Essen Essen Germany.ORCID 0000-0002-2685-9732
Andreas StangInstitute for Medical Informatics, Biometry and Epidemiology, Medical Faculty University Duisburg-Essen Essen Germany.
Nils KuklikInstitute for Medical Informatics, Biometry and Epidemiology, Medical Faculty University Duisburg-Essen Essen Germany.ORCID 0000-0001-9811-0694
Marcus BrinkmannInstitute for Medical Informatics, Biometry and Epidemiology, Medical Faculty University Duisburg-Essen Essen Germany.ORCID 0000-0001-6370-5380
Martin GrondDepartment of Neurology Siegen Hospital Siegen Germany.ORCID 0009-0001-7732-2345
Jens D RollnikInstitute for Neurorehabilitation Research (InFo), BDH-Clinic Hessisch Oldendorf, Affiliated Institute of Hannover Medical School Hessisch Oldendorf Germany.ORCID 0000-0003-0034-4607
Lars MarquardtUniversity Department of Neurology, Asklepios Hospital Hamburg Wandsbek, Faculty of Medicine Semmelweis University Campus Hamburg Hamburg Germany.
Andrea KraftDepartment of Neurology Martha-Maria Hospital Halle Halle Germany.ORCID 0009-0001-3748-1798
Eckhard SchlemmDepartment of Neurology University Medical Center Hamburg-Eppendorf Hamburg Germany.ORCID 0000-0002-5729-2935
Carsten EggersDepartment of Neurology Knappschaftskrankenhaus Bottrop GmbH Bottrop Germany.
Christoph C EschenfelderHuman Pharma Germany Boehringer Ingelheim Pharma GmbH & Co. KG Ingelheim Germany.ORCID 0000-0003-2766-2488
Christian WeimarInstitute for Medical Informatics, Biometry and Epidemiology, Medical Faculty University Duisburg-Essen Essen Germany.
Hans-Christoph DienerInstitute for Medical Informatics, Biometry and Epidemiology, Medical Faculty University Duisburg-Essen Essen Germany.ORCID 0000-0002-6556-8612

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOral anticoagulation is highly effective in preventing ischemic events in patients with atrial fibrillation. Still, a considerable number of patients have an acute ischemic stroke or transient ischemic attack despite anticoagulation. In this study, we investigated the association of prior antithrombotic regimens with stroke severity, volume, and hemorrhagic transformation. METHODS AND

resultsThis is a post hoc analysis of the prospective, multicenter, observational PRODAST (Prospective Record of the Use of Dabigatran in Patients With Acute Stroke or TIA) study, which was conducted in 86 stroke units in Germany between July 2015 and November 2020. In 9030 patients with atrial fibrillation who had an acute ischemic stroke or transient ischemic attack within 7 days before enrollment, we analyzed the association of anticoagulants in comparison to lack of prevalent antithrombotic treatment with clinical stroke severity, infarct size, and risk for hemorrhagic transformation. A total of 4479 patients had prior anticoagulation at the time of index event. After adjustment for confounders (arterial hypertension, diabetes, heart failure, age, and sex), patients with prior anticoagulation had less severe strokes (-2.5 National Institutes of Health Stroke Scale points [95% CI, -2.8 to -2.2]), smaller infarct sizes (-23 mL [95% CI, -44 mL to -2 mL], n=4041), and reduced odds for hemorrhagic transformation (5% versus 10%; odds ratio, 0.48 [95% CI, 0.40-0.57]) compared with patients without antithrombotic treatment. These findings were confirmed using sensitivity analyses accounting for thrombolysis and mechanical thrombectomy, as well as timing of brain imaging. Antiplatelet therapy had hardly any association with the end points compared with no antithrombotic pretreatment.

conclusionsPrior anticoagulation was not only associated with less severe stroke and smaller infarct size but also with a reduced risk of hemorrhagic transformation compared with no antithrombotic pretreatment. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02507856.

Indexed as

AnticoagulantsAntithrombinsAtrial FibrillationDabigatranIntracranial HemorrhagesIschemic Attack, TransientIschemic StrokeStrokeAgedAged, 80 and overFemaleGermanyHumansMaleMiddle AgedProspective StudiesAnticoagulantsAntithrombinsDabigatranacute ischemic strokeanticoagulationhemorrhagic transformationintracranial hemorrhagesecondary preventiontransient ischemic attackvitamin K antagonists

Identifiers

PMID39895532
PMCPMC12074706

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.